Literature DB >> 20303152

Detection rates of nonpalpable prostate cancer in Korean men with prostate-specific antigen levels between 2.5 and 4.0 ng/mL.

Hong Seok Kim1, Seong Soo Jeon, Jae Duck Choi, Wansuk Kim, Deok Hyun Han, Byong Chang Jeong, Seong Il Seo, Kyu Sung Lee, Sung Won Lee, Hyun Moo Lee, Han Yong Choi.   

Abstract

OBJECTIVE: To evaluate the detection rate and pathology of cancer in Korean men with low levels of prostate-specific antigen (PSA), 2.5-4.0 ng/mL.
METHODS: We examined 1097 patients with PSA level of 2.5-10.0 ng/mL, who underwent transrectal ultrasonography-guided prostate needle biopsies between January 2008 and March 2009. Of the 1097 biopsy patients, 815 met our criteria of benign findings by digital rectal examination and the absence of cancerous lesions by TRUS. Clinical characteristics and detection rates of prostate cancer, as well as the pathology of specimens obtained by needle biopsies and prostatectomies, were evaluated in these patients.
RESULTS: Of the 815 patients, 349 had group 1 (PSA level, 2.5-4.0 ng/mL) and 466 had group 2 (PSA level, 4.0-10.0 ng/mL). The percentage of patients diagnosed with prostate cancer was not statistically different between the 2 groups (21.8% in group 1, and 20.2% in group 2). In group 1, 70.7% of patients had a pathologic Gleason score of 7 or higher and 91.4% had organ-confined tumors (pT2). The pathologic characteristics, including Gleason score, pathologic stage, and percentage of insignificant cancer were similar in prostatectomy specimens between group 1 and group 2.
CONCLUSIONS: Detection rates of nonpalpable prostate cancer in Korean men were 21.8% in group 1 and 20.2% in group 2 without statistically significant difference. Pathologic characteristics of prostatectomy specimens also were similar between group 1 and group 2. These results suggest that a lower PSA level might be considered as an indication for prostate biopsy.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303152     DOI: 10.1016/j.urology.2009.12.036

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  The likelihood of having a serum PSA level of ≥2.5 ng/mL according to the degree of fatty liver disease in a screened population.

Authors:  Jong Hyun Yoon; Hee Jo Yang; Jae Heon Kim; Seung Whan Doo; Won Jae Yang; Jiyoung Hwang; Seong Sook Hong; Suyeon Park; Dae Yeon Cho
Journal:  Can Urol Assoc J       Date:  2015-12-14       Impact factor: 1.862

2.  The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng ml(-1) according to obesity in a screened Korean population.

Authors:  Won Jae Yang
Journal:  Asian J Androl       Date:  2013-08-05       Impact factor: 3.285

3.  Are clinically insignificant prostate cancers really insignificant among Korean men?

Authors:  Chan Dong Yeom; Seung Hwan Lee; Kyung Kgi Park; Sang Un Park; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

4.  Correlation between Gleason score distribution and Prostate Health Index in patients with prostate-specific antigen values of 2.5-10 ng/mL.

Authors:  Joongwon Choi; Minyong Kang; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee
Journal:  Investig Clin Urol       Date:  2020-11

5.  Usefulness of MRI targeted prostate biopsy for detecting clinically significant prostate cancer in men with low prostate-specific antigen levels.

Authors:  Seokhwan Bang; Jiwoong Yu; Jae Hoon Chung; Wan Song; Minyong Kang; Hyun Hwan Sung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Il Seo; Hyun Moo Lee; Seong Soo Jeon
Journal:  Sci Rep       Date:  2021-11-09       Impact factor: 4.379

6.  Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml.

Authors:  Rui Su; Jin-Feng Pan; Da-Wei Ren; Jun-Hui Jiang; Qi Ma
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.